Together we can end breast cancer.

Anne has lived with breast cancer since she was ten years old. 

That’s how old she was when her mother found a lump. Only 38 years old at the time, Mariela was a busy woman with two kids in the middle of planning a move. Like far too many women, she didn’t prioritize getting to the doctor quickly.  The breast cancer had spread to her lymph nodes by the time she received a diagnosis.

The aggressive treatment that Mariela received saved her life. It also made an indelible impression on Anne.  Even at a young age, she understood the toll the chemotherapy and radiation took on her mother.  Ultimately, that personal experience fueled her involvement with The Lynn Sage Foundation Board of Directors.

Mariela beat her breast cancer in 1993 and eventually moved to southern California, living a healthy and full life. It was twenty years later that she received news far too many survivors hear. The breast cancer that infected her lymph nodes all those years ago had now metastasized to her bones.  Unfortunately, few statistics are collected for metastatic breast cancer, but estimates suggest that 20-30% of patients will experience late recurrence.

Today, Anne travels from Chicago to Los Angeles every other week. She visits her parents, attends doctor’s appointments, and helps care for her mother.  She is astounded by the evolution of cancer treatment she observes.

“I remember how aggressive the chemotherapy was before. Science has evolved so much since then.  My mom has had a very stable, normal life these past four years, all while living with cancer again.  This time, her treatment could be targeted to specific cells and, at least in the beginning, was less aggressive.  She was even able to open a pilates studio while undergoing treatment.  Her attitude, her medical team and the treatment have all just been remarkable!”

The targeted treatment Mariela receives now resulted from years of diligent and extensive research. Witnessing the difference research advances like these make in her own mother’s life, Anne is convinced that science is the key to either cure or prevent this terrible disease.

“I’ve met the Lynn Sage Scholars and toured their labs.  It’s so fascinating how they can identify the different cells and specifically target them.  I’ve seen how far we’ve come and can only imagine what the next 10-20 years will bring!  At the end of the day, breast cancer research is the only thing that will make a difference.”

The research that led to Mariela's targeted treatment is driving novel research being conducted by one of the current Lynn Sage Scholars. Dr. Marc Mendillo is investigating a new approach to the progression of tumors, metastasis and targeted therapeutics.

As passionate as she is about finding a cure, Anne is equally passionate about women being proactive about their health.  She can’t help but wonder what would have happened if her mother’s original breast cancer had been diagnosed earlier.

“If my mom had gotten her cyst removed on time, perhaps we wouldn’t be here.  If you notice anything abnormal, get it screened and tested!  Women get nervous about going to the doctor, but that’s the wrong attitude.  It’s a win/win situation. If it’s nothing, you’re good.  If it’s something, it will be handled ASAP.”

Anne has hardly known a life without breast cancer. But, she knows better than most the impact research makes on the quality of life for patients like her mother.  This Mother’s Day, celebrate all mothers who live with strength and grace in the face of breast cancer.  Support The Lynn Sage Foundation and research that allows them to do just that.   

We are excited to host our Fifth Annual Summer Toast at Proxi, a beautiful new restaurant in Chicago, on Thursday, June 8th.  We would love to see you there!  Please visit lynnsagefoundation.org for more information.  

Warm Regards, 

Laura & Halee 

Links:

• The Lynn Sage Foundation

Thanks to the incredible generosity of The Lynn Sage Foundation community, we are thrilled to announce Dr. Dai Horiuchi as our THIRD Lynn Sage Scholar in 2017!

Dr. Horiuchi is an Associate Professor of Pharmacology at Northwestern University Feinberg School of Medicine, and a member of the Translational Research in Solid Tumors Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.  The goal of his ongoing basic and translational breast cancer research is to identify and validate novel therapeutic strategies for triple-negative breast cancer (TNBC), which is the breast cancer subtype with the poorest clinical outcome. Triple-negative tumors present serious challenges due to limited insights into the mechanisms of tumor generation and progression, as well as a lack of validated therapeutic targets. 

The past two decades of breast cancer research have given rise to some molecularly targeted therapies and gene expression-based diagnostic tools. These clinical tools have helped to slow disease progression in some forms of breast cancer and have helped doctors predict who has a higher likelihood of responding to a given therapy, thus paving the way to the era of personalized medicine. However, doctors still face a significant number of breast cancer patients who either do not respond well to any existing therapies or eventually experience a recurrence of tumors that have become resistant to therapies which were previously effective. These cases account for the actual breast cancer-related mortality rate, which has not substantially improved over the past decade.  This is particularly the case for patients with TNBC.

Dr. Horiuchi’s laboratory is poised to better understand the biology of these tumors and to validate novel therapeutic concepts, setting the foundation for early stage human clinical trials.  In collaboration with clinicians at Northwestern Medicine and with pharmaceutical partners, Dr. Horiuchi is dedicated to bringing his laboratory findings to clinical testing.  His overarching goal is to significantly reduce TNBC-related mortality for the estimated 35% of patients in need of life-saving treatment.

Because of your wonderful generosity, The Lynn Sage Foundation is proud to include Drs. Dai Horiuchi, Marc Mendillo, and Abde Abukhdeir in the Lynn Sage Scholars program for 2017.   Please consider continuing your support.  Together, we will change the trajectory of breast cancer. 

With deepest gratitude,

Laura & Halee

Links:

• The Lynn Sage Foundation